Wegovy Mechanism of Action: The Full Semaglutide 2.4 mg Pathway

What Semaglutide Actually Is: Structure and Pharmacology

Semaglutide is a synthetic analog of human glucagon-like peptide-1, sharing 94% amino-acid sequence identity with native GLP-1(7-36)amide. Three engineered modifications distinguish it from the endogenous hormone and explain its once-weekly dosing schedule.

First, an alpha-aminoisobutyric acid (Aib) substitution at position 8 renders the molecule resistant to cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that degrades native GLP-1 within 2 to 3 minutes of secretion 1. Second, a lysine-to-arginine change at position 34 directs fatty-acid acylation to lysine-26 exclusively. Third, a C-18 fatty diacid chain conjugated at position 26 via a linker enables strong, reversible binding to serum albumin 1. This albumin binding slows renal clearance and creates a plasma half-life of approximately 165 to 168 hours. Native GLP-1 lasts minutes. Semaglutide lasts a week. That single pharmacokinetic difference is why patients inject once every seven days rather than continuously.

The Wegovy formulation delivers semaglutide at 2.4 mg per week after a 16-week dose-escalation protocol (0.25 mg for 4 weeks, then 0.5, 1.0, and 1.7 mg in 4-week steps) designed to reduce gastrointestinal side effects 2. At the 2.4 mg maintenance dose, steady-state plasma concentrations reach approximately 50 nmol/L, a level that saturates peripheral GLP-1 receptors and activates central receptors at concentrations sufficient for meaningful appetite suppression 1.

Central Nervous System: How Wegovy Suppresses Appetite

The largest share of semaglutide's weight-loss effect comes from reduced caloric intake, not from changes in energy expenditure. The drug achieves this through direct and indirect action on two brain regions: the hypothalamic arcuate nucleus (ARC) and the nucleus tractus solitarius (NTS) in the brainstem.

GLP-1 receptors in the ARC are expressed on pro-opiomelanocortin (POMC) neurons, which produce the anorexigenic peptide alpha-melanocyte-stimulating hormone (alpha-MSH). Semaglutide activates these neurons, increasing alpha-MSH release and signaling satiety through melanocortin-4 receptors (MC4R) in the paraventricular nucleus 3. Simultaneously, it inhibits neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the ARC, which are orexigenic. The net result is a shift in hypothalamic tone toward reduced hunger and earlier meal termination.

In the brainstem, GLP-1 receptors on NTS neurons integrate vagal afferent signals from the gut with descending inputs from the hypothalamus. Semaglutide amplifies post-meal satiety signals arriving via the vagus nerve, making patients feel full sooner and for longer 4. Functional MRI studies in humans have confirmed that semaglutide reduces activation in brain regions associated with food reward and craving, including the insula and orbitofrontal cortex 5. Participants on semaglutide 2.4 mg reported less food craving and a reduced preference for high-fat foods in validated food-preference questionnaires.

Ad libitum feeding studies show that semaglutide 2.4 mg reduces daily caloric intake by 24 to 35%, corresponding to roughly 500 to 700 fewer kilocalories per day 4. That caloric deficit, sustained over 68 weeks, accounts for the 14.9% mean body-weight reduction observed in STEP-1 6.

Gastrointestinal Effects: Gastric Emptying and Gut Peptide Signaling

Semaglutide slows gastric emptying, a peripheral mechanism that complements its central appetite effects. After a standardized meal, gastric half-emptying time increases by approximately 30 to 40% during the first postprandial hour in patients receiving semaglutide versus placebo 7. This delay prolongs gastric distension, which activates mechanoreceptors and vagal afferents that signal fullness to the NTS.

The effect on gastric motility is most pronounced during the dose-escalation phase and appears to attenuate partially at steady state. A pharmacokinetic-pharmacodynamic analysis of semaglutide 1.0 mg (the diabetes dose) found that the gastric-emptying delay was greatest at week 12 and less pronounced by week 31, suggesting tachyphylaxis of the peripheral GI effect even as weight loss continues 7. This observation supports the view that central appetite suppression, not gastric slowing alone, drives the sustained weight-loss trajectory.

Semaglutide also suppresses postprandial glucagon secretion from pancreatic alpha cells in a glucose-dependent manner 2. By reducing glucagon, it lowers hepatic glucose output and blunts postprandial glucose excursions. In patients without diabetes, this manifests as more stable blood-glucose profiles throughout the day. The glucose-dependent nature of this suppression is clinically relevant because it means the drug carries minimal standalone hypoglycemia risk when used without sulfonylureas or insulin.

Pancreatic Beta-Cell Effects and Insulin Dynamics

GLP-1 receptor activation on pancreatic beta cells enhances glucose-stimulated insulin secretion (GSIS) through a well-characterized cAMP-PKA-Epac2 signaling cascade. Semaglutide binding triggers adenylyl cyclase activation, raising intracellular cAMP, which potentiates calcium-dependent exocytosis of insulin granules 8.

This effect is glucose-dependent. Below a plasma glucose threshold of approximately 65 mg/dL (3.6 mmol/L), GLP-1 receptor-mediated insulin secretion effectively shuts off 8. That built-in glucose switch is why semaglutide monotherapy produces very low rates of hypoglycemia. In STEP-1, clinically significant hypoglycemia (blood glucose <54 mg/dL) occurred in 0% of semaglutide-treated participants who were not on concomitant insulin or sulfonylureas 6.

Animal data and in vitro studies indicate that GLP-1 receptor agonists also promote beta-cell proliferation and inhibit apoptosis, effects mediated through cAMP-responsive element-binding protein (CREB) and IRS-2 signaling 8. Whether these trophic effects translate meaningfully to human beta-cell mass preservation during long-term treatment remains unconfirmed. Post-mortem and imaging data in humans are limited, and extrapolating rodent islet biology to human physiology requires caution.

Cardiovascular Mechanism: Beyond Weight Loss

The SELECT trial (N=17,604) demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) with semaglutide 2.4 mg versus placebo over a median 39.8 months of follow-up in adults with established cardiovascular disease and overweight or obesity but without diabetes 9. The hazard ratio was 0.80 (95% CI, 0.72 to 0.90; P<0.001).

The cardiovascular benefit likely extends beyond weight loss itself. GLP-1 receptors are expressed on vascular endothelial cells, smooth muscle cells, and cardiomyocytes. Preclinical and translational evidence points to several direct vascular effects of GLP-1 receptor agonism.

Semaglutide reduces systemic inflammation. In SUSTAIN-6 and SELECT, C-reactive protein (CRP) levels fell by 35 to 40% from baseline in semaglutide-treated participants 9. It also reduces systolic blood pressure by 3 to 5 mmHg, an effect seen consistently across STEP and SUSTAIN trials and likely mediated by improved endothelial nitric oxide signaling and natriuresis 10. Small but consistent reductions in LDL cholesterol (3 to 5%), triglycerides (12 to 15%), and waist circumference provide additional cardiometabolic benefit.

Dr. A. Michael Lincoff, lead investigator of SELECT, stated: "The cardiovascular benefit of semaglutide 2.4 mg was consistent across prespecified subgroups and was evident as early as the first planned interim analysis" 9.

The STEP-1 Trial: Quantifying the Mechanism in Practice

STEP-1 remains the key registration trial for Wegovy. This randomized, double-blind, placebo-controlled study enrolled 1,961 adults with BMI ≥30 kg/m² (or ≥27 kg/m² with at least one weight-related comorbidity) without diabetes across 129 sites in 16 countries 6.

Participants received semaglutide 2.4 mg or placebo subcutaneously once weekly for 68 weeks, plus lifestyle intervention (500 kcal/day deficit counseling and 150 min/week physical activity). The co-primary endpoints were percent change in body weight and the proportion achieving ≥5% weight loss.

Results were unambiguous. Mean weight change was -14.9% with semaglutide versus -2.4% with placebo (estimated treatment difference: -12.4 percentage points; 95% CI, -13.4 to -11.5; P<0.001). A total of 86.4% of semaglutide participants lost ≥5% body weight versus 31.5% on placebo, and 69.1% lost ≥10% versus 12.0% 6. One in three semaglutide-treated participants (32.0%) achieved ≥20% weight loss.

The weight-loss curve in STEP-1 did not plateau until approximately weeks 60 to 68, suggesting that the full mechanistic effect of semaglutide at 2.4 mg requires over a year of continuous treatment to reach equilibrium. Gastrointestinal adverse events were the most common side effects: nausea (44.2% vs. 17.4%), diarrhea (31.5% vs. 16.2%), and vomiting (24.8% vs. 6.4%), with most events graded mild to moderate and occurring predominantly during dose escalation 6.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists including semaglutide 2.4 mg as first-line pharmacotherapy for adults with BMI ≥30 or ≥27 with complications, citing the STEP program as Level 1 evidence 11.

Why Weight Regain Occurs After Discontinuation

STEP-1 extension data and the dedicated STEP-4 withdrawal trial showed that participants who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within one year of discontinuation 12. This pattern is consistent with the understanding that semaglutide suppresses appetite through continuous receptor occupancy, not through permanent resetting of a body-weight set point.

Obesity involves chronically dysregulated energy-homeostasis circuits. Weight loss triggers compensatory increases in ghrelin, reductions in leptin, and heightened AgRP/NPY activity that collectively drive weight regain. Semaglutide overrides these compensatory signals while present, but the signals reassert themselves when the drug is withdrawn 3. This biology supports the clinical consensus that semaglutide, like antihypertensives for blood pressure, requires continued use to maintain its effect.

Dr. Robert Kushner, co-investigator on the STEP trials, has noted: "Obesity is a chronic disease with biological drivers that persist after weight loss. The expectation should be long-term treatment, not a short course" 12.

Putting the Pathway Together: From Injection to Clinical Outcome

The full mechanistic sequence begins with subcutaneous injection and albumin binding, which creates a slow-release depot. Over the following 24 to 72 hours, free semaglutide reaches peak plasma concentrations and distributes to target tissues. Central GLP-1 receptor activation in the ARC and NTS reduces hunger, food craving, and caloric intake. Peripheral activation slows gastric emptying (most prominently in early treatment), improves glucose-dependent insulin secretion, and suppresses inappropriate glucagon release. Anti-inflammatory and vasoprotective effects contribute to cardiovascular risk reduction independent of weight. These parallel pathways converge on a sustained negative energy balance that produces clinically meaningful weight loss when the drug is maintained at therapeutic concentrations.

The 2.4 mg dose used in Wegovy, rather than the 1.0 mg dose used in Ozempic for type 2 diabetes, achieves higher steady-state plasma levels that maximize central appetite suppression. Dose-response modeling from phase 2 trials showed that weight loss increased from approximately 6% at 0.4 mg to 13.8% at 0.4 mg weekly, with 2.4 mg selected as the dose providing near-maximal efficacy on the weight-loss dose-response curve without disproportionate GI adverse events 13.

Patients starting Wegovy should expect nausea in the first 8 to 12 weeks (during dose escalation), appetite reduction within the first 2 to 4 weeks, and measurable weight loss of 5% or more by weeks 12 to 16, with continued loss through week 60 to 68 at the 2.4 mg maintenance dose.